- Home
- SBXD vs MNPR Comparison
SBXD vs MNPR Comparison
Compare SBXD & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBXD
- MNPR
- Stock Information
- Founded
- SBXD 2024
- MNPR 2014
- Country
- SBXD United States
- MNPR United States
- Employees
- SBXD N/A
- MNPR N/A
- Industry
- SBXD
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- SBXD
- MNPR Health Care
- Exchange
- SBXD NYSE
- MNPR Nasdaq
- Market Cap
- SBXD 257.1M
- MNPR 249.5M
- IPO Year
- SBXD 2024
- MNPR 2019
- Fundamental
- Price
- SBXD $10.38
- MNPR $33.82
- Analyst Decision
- SBXD
- MNPR Strong Buy
- Analyst Count
- SBXD 0
- MNPR 5
- Target Price
- SBXD N/A
- MNPR $59.50
- AVG Volume (30 Days)
- SBXD 59.6K
- MNPR 18.3K
- Earning Date
- SBXD 01-01-0001
- MNPR 05-13-2025
- Dividend Yield
- SBXD N/A
- MNPR N/A
- EPS Growth
- SBXD N/A
- MNPR N/A
- EPS
- SBXD N/A
- MNPR N/A
- Revenue
- SBXD N/A
- MNPR N/A
- Revenue This Year
- SBXD N/A
- MNPR N/A
- Revenue Next Year
- SBXD N/A
- MNPR N/A
- P/E Ratio
- SBXD $50.52
- MNPR N/A
- Revenue Growth
- SBXD N/A
- MNPR N/A
- 52 Week Low
- SBXD $9.95
- MNPR $1.72
- 52 Week High
- SBXD $10.82
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- SBXD N/A
- MNPR 40.83
- Support Level
- SBXD N/A
- MNPR $37.81
- Resistance Level
- SBXD N/A
- MNPR $44.40
- Average True Range (ATR)
- SBXD 0.00
- MNPR 3.89
- MACD
- SBXD 0.00
- MNPR -1.03
- Stochastic Oscillator
- SBXD 0.00
- MNPR 3.62
About SBXD SILVERBOX CORP IV
SilverBox Corp IV is a blank check company.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.